Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities

  • Front Immunol. 2021 Jul 27:12:725330. doi: 10.3389/fimmu.2021.725330.
Yifan Xu  1  2 ,  Jin Jiang  3 ,  Yutong Wang  1  2 ,  Wei Wang  4 ,  Haokun Li  1  2 ,  Wenyu Lai  1  2 ,  Zhipeng Zhou  1  2 ,  Wei Zhu  5 ,  Zheng Xiang  6 ,  Zhiming Wang  7 ,  Zhe Zhu  8 ,  Lingfeng Yu  9 ,  Xiaolan Huang  4 ,  Hua Zheng  10 ,  Sha Wu  2  11
Affiliations
  • 1. Microbiome Medicine Center, Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
  • 2. Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
  • 3. Guangzhou Blood Center, Department of Blood Source Management, Guangzhou, China.
  • 4. Department of Obstetrics and Gynecology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • 5. Hepatology Unit and Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • 6. Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
  • 7. State Key Laboratory of Esophageal Cancer Prevention & Treatment, Sino-British Research Center for Molecular Oncology, National Center for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.
  • 8. Huikezhe Biological Tech. Beijing, R&D Department, Beijing, China.
  • 9. School of Basic Medicine Science, Tianjin Medical University, Tianjin, China.
  • 10. Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • 11. National Demonstration Center for Experimental Education of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
PMID: 34386017 DOI: 10.3389/fimmu.2021.725330
Abstract

Gynecologic malignancies, mainly including Ovarian Cancer, Cervical Cancer and Endometrial Cancer, are leading causes of death among women worldwide with high incidence and mortality rate. Recently, adoptive T cell therapy (ACT) using engineered T cells redirected by genes which encode for tumor-specific T cell receptors (TCRs) or chimeric antigen receptors (CARs) has demonstrated a delightful potency in B cell lymphoma treatment. Researches impelling ACT to be applied in treating solid Tumors like gynecologic Tumors are ongoing. This review summarizes the preclinical research and clinical application of engineered T cells therapy for gynecologic Cancer in order to arouse new thoughts for remedies of this disease.

Keywords
CAR-T; TCR-T; adoptive T cell therapy; engineered T cells; gynecologic malignancies; immunotherapy.